Operator

Good afternoon, and thank you for joining LeonaBio's key opinion leader call. [Operator Instructions] A replay of today's event will be available on the Investors section of the LeonaBio website.

I would now like to turn the call over to Mark Litton, President and CEO of LeonaBio.

Mark Litton
President, CEO & Director

Thank you, Elissa; and good afternoon, everyone. I'm Mark Litton, President and CEO of LeonaBio. On behalf of our entire team, thank you for joining us today for a discussion on modulation and combination, unlocking the potential for lasofoxifene to transform the standard of care in metastatic breast cancer.

Next slide, please. We are pleased today to be joined by 2 world-leading breast cancer physicians and researchers who sit at the forefront of clinical care, translational science and drug development. Together, we'll discuss the rapidly evolving treatment landscape in ER-positive metastatic breast cancer, the challenges patients continue to face, particularly those with endocrine-resistant disease and the opportunity we believe lasofoxifene represents within this shifting paradigm.

Next slide. Before we begin, I'd like to remind you that during today's call, we will be making forward-looking statements. Such forward-looking statements involve risks and uncertainties. Please refer to our filings with the SEC or on the Investors section of the LeonaBio website for more information concerning the risk factors that could affect the company. In addition, I'd like to note that the views expressed by our physician experts